TON - March 2018, Vol 11, No 1

Beth Faiman, PhD, APRN-BC, AOCN, is an author, presenter, and educator on the topics of multiple myeloma, general cancer diagnosis and treatment, and management of skeletal and other cancer-related complications.

According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied.

According to data presented at ASH 2017, patients with multiple myeloma who received injectable therapy used significantly more disability benefits and incurred higher productivity costs than patients who received oral medications.

In this study, patients with hematologic malignancies and IDH1 mutation were enrolled in a dose-escalation stage in which ivosidenib was given at 100 mg twice daily, or in doses ranging from 200 mg to 1200 mg once daily.

AONN+ is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. This particular meeting was all about metrics.

The phase 3 study LORELEI compared neoadjuvant therapy with letrozole plus placebo versus letrozole plus taselisib, a PI3K inhibitor, in this patient population.“

There is only one “king of the road” when it comes to dealing with the adverse side effects of oral cancer drugs, and that is not the healthcare professional, according to Christine B. Boers-Doets, MSc. She discussed this topic at the recent ESMO International Consensus Conference for Advanced Breast Cancer in Lisbon, Portugal.

The American Academy of Nursing (AAN) released its position statement in recognition that safe nursing practice requires adequate, high-quality sleep to allow them to contribute to patient care safely.

At least 3 clinical laboratories offer targeted panels for inherited prostate cancer. In addition, other laboratories analyze genes associated with prostate cancer risk, although they are not part of a targeted, inherited prostate cancer panel.

Advocacy usually begins with personal crisis and the need for support, but it eventually moves on to sharing experiences and information with others, speaking out in public forums, and working to influence change, suggested Musa Mayer, breast cancer survivor and advocate, at the recent ESMO International Consensus Conference for Advanced Breast Cancer in Lisbon, Portugal.

Page 1 of 2
Results 1 - 10 of 17